Current and completed investments

Sciety is specialized in growth companies in life science. We invest in biotechnology, health tech, ICT in healthcare, pharmaceuticals, and medical technology.

Current investments

We have one or more companies open for investments. Please login or create an account to learn more and invest.

Completed investments

NEOGAP Therapeutics AB

NEOGAP has a unique approach to train the patient’s immune system to target tumour-specific mutations, so called neoantigens to eradicate the cancer. The treatment has the potential to kill the cancer cells while leaving healthy cells untouched, which significantly reduces the risk of side effects.

SAGA Diagnostics

SAGA Diagnostics develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment. The tests are based on the company’s proprietary technologies for analyzing circulating tumor DNA (ctDNA).

Capitainer

Capitainer supplies intelligent solutions for self-sampling of blood and plasma. The product qDBS is based on DBS (Dried Blood Spot) technology and is designed for easy home sampling of blood with high precision.

PharmNovo

PharmNovo develops drugs for chronic pain based on a new type of selective delta opioids. The main candidate PN6047 shows promising results on effective pain relief without negative side effects.

Exits

Cartana

Cartana’s patent-applied research tool revolutionizes the possibility of analyzing tissue samples, providing pharmaceutical companies with important information in their quest for new treatments.

Read more

Inhalation Sciences

Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.

Read more

Attana

With Attana’s patented technology, pharmaceutical companies can evaluate, in an early development stage, how drug candidates impact the body and can identify the risk of side effects.

Read more

Lipigon Pharmaceuticals

Lipigon develops orphan drugs for illnesses due to disorders in how the body handles fat. The company’s major program, Lipsense, focuses on the illness, HoFH, where there is, today, no sufficient treatment.

Read more